Restenosis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Restenosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Restenosis - Pipeline Review, H2 2016', provides an overview of the Restenosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Restenosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Restenosis
- The report reviews pipeline therapeutics for Restenosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Restenosis therapeutics and enlists all their major and minor projects
- The report assesses Restenosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Restenosis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Restenosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Restenosis Overview 6
Therapeutics Development 7
Pipeline Products for Restenosis - Overview 7
Pipeline Products for Restenosis - Comparative Analysis 8
Restenosis - Therapeutics under Development by Companies 9
Restenosis - Therapeutics under Investigation by Universities/Institutes 10
Restenosis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Restenosis - Products under Development by Companies 13
Restenosis - Products under Investigation by Universities/Institutes 14
Restenosis - Companies Involved in Therapeutics Development 15
Bio3 Research S.r.l 15
CytoTools AG 16
XBiotech Inc 17
Restenosis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
(connective tissue growth factor + insulin human) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
alendronate sodium - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
CV-18C3 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
didox - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
HMW-02Ak - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
HMW-02Ap - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
HO-3867 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
TW-01 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Restenosis - Dormant Projects 41
Restenosis - Discontinued Products 43
Restenosis - Product Development Milestones 44
Featured News & Press Releases 44
Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a For Restenosis 44
Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease 44
Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites 45
Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Number of Products under Development for Restenosis, H2 2016 7
Number of Products under Development for Restenosis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Restenosis - Pipeline by Bio3 Research S.r.l, H2 2016 15
Restenosis - Pipeline by CytoTools AG, H2 2016 16
Restenosis - Pipeline by XBiotech Inc, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Assessment by Combination Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Restenosis - Dormant Projects, H2 2016 41
Restenosis - Dormant Projects (Contd..1), H2 2016 42
Restenosis - Discontinued Products, H2 2016 43